Akamai Technologies, Inc.

The full register, from 13F filings

The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 753 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.

Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.

What a reader needs to know to read these numbers

• Holdings side: searched Akamai's most recent 10-Q (period 30 Jun 2026, filed 7 Aug 2026) for 'equity investment', 'non-marketable', 'privately held', 'equity method', 'joint venture', 'unrealized gain', 'cost method', 'strategic investment', 'Investment in', 'noncontrolling', 'investee'; only 'cost method' and 'unrealized gain' hit, both in non-GAAP reconciliation tables with no balance-sheet detail note in the interim filing (Akamai's 10-Qs do not repeat the annual cost-method-investments note). Searched the most recent 10-K (fiscal year ended 31 Dec 2025, filed 20 Feb 2026) for the same terms and found the actual note: 'Cost Method Investments... consist primarily of equity securities of companies which do not have readily determinable fair values, and in which the Company does not have the ability to exercise significant influence... As of December 31, 2025 and 2024, the carrying amount of the Company's cost method investments was $31.7 million and $20.5 million, respectively, and are included in other assets in the consolidated balance sheets.' No investee is named anywhere in either filing. Per this project's rule that a combined balance covering unnamed investees sizes none of them individually, no holdings row is created; the $31.7 million bucket (as of 31 Dec 2025, the latest disclosed figure) is recorded here as a genuine but unsized negative rather than a gap left to speak for itself.
• The same 10-K note also discloses an Equity Method Investment: a joint venture with Mitsubishi UFJ Financial Group (MUFG) called Global Open Network, Inc. ('GO-NET'), intended to operate a blockchain-based payment network. GO-NET's operations were suspended in February 2022 and it was liquidated in August 2023; Akamai's final gain from the liquidation was recorded in 2023 and the 10-K states 'We do not expect additional activity related to this investment.' There is no current GO-NET balance or holding as of 30 Jun 2026, so no row is created for it either; it is a closed, historical position.
• Exhibit 21.1 of the 10-K (subsidiaries list, as of 31 Dec 2025) was checked as the brief suggests: it is a bare name/jurisdiction list of Akamai's own wholly owned operating subsidiaries (Akamai Technologies Limited, Akamai Technologies GmbH, Akamai Technologies India Private Ltd. and dozens more), no ownership-percentage column, and no privately held investee named anywhere on it. Treated as a genuine negative, consistent with the $31.7 million cost-method bucket being the only holdings-adjacent disclosure found in either filing.
• Akamai's convertible senior notes (0.375% due 2027, 1.125% due 2029, 0.250% due 2030, and related instruments) are Akamai's OWN debt, issued by the company, not a holding. Confirmed via the 10-Q's Note 7 (Debt) and independently cross-checked: these notes appear as distinct CUSIPs (00971TAL5, 00971TAN1, 00971TAQ4) inside nearly every institutional holder's own 13F-HR examined for this file (BlackRock, State Street, Fidelity, Invesco, Point72, Bank of America, Morgan Stanley, BNY Mellon, Goldman Sachs, Capital Group), correctly excluded from every register row above as debt rather than equity. One filer quirk worth recording: Goldman Sachs' 13F-HR labels these same notes '[CNV]' rather than '[NOTE ...%]', which this project's filing.py derivative-title regex does not catch by title text alone; verified manually via the shared CUSIP match against other filers' explicitly-labeled note lines before excluding them from consideration (Goldman Sachs itself was not included as a register row in this file, so this did not affect a shipped number, but is recorded for future reference).
• Self-gate computed from this final file: 13 register rows. Members: Tom Leighton (2,759,456 sh) rolls up into the 'All executive officers and directors as a group (18 persons)' aggregate, which is reduced by that amount for the total (3,317,206 - 2,759,456 = 557,750 residual), per the chart's own arithmetic; no other row rolls into another. Total = 18,059,705 (Vanguard) + 11,324,134 (Capital Group) + 10,461,720 (BlackRock) + 5,774,426 (State Street) + 4,752,119 (First Trust) + 4,226,353 (Geode) + 3,913,562 (Invesco) + 3,568,226 (Bank of America) + 2,575,659 (Point72) + 2,359,623 (Fidelity/FMR) + 214,492 (T. Rowe Price) + 2,759,456 (Tom Leighton, full value as a member) + 557,750 (officers/directors aggregate residual) = 70,547,225 shares, against shares_outstanding 143,716,609 = 49.09% of the company.
• That 49.09% sits above the roughly 25-45% band this project's brief expects, and the cause was investigated rather than shipped blind: it is not a computational defect. Every institutional row's implied price (value_usd divided by shares) clusters tightly around $118.2 per share as of 30 Jun 2026 (Vanguard family ~$118.4, Capital Group family ~$118.2, BlackRock ~$118.2, State Street ~$118.2, First Trust ~$118.2, Geode ~$118.7, Invesco ~$118.2, Bank of America ~$118.2, Point72 ~$118.2, Fidelity ~$118.2, T. Rowe Price ~$118.2 after the thousands conversion), confirming one consistent instrument, basis and price across every filer with no unit-mixing error. No family is double counted: Capital Group's two checked-and-zero registrants (Capital Research Global Investors, Capital International Investors) were confirmed to hold nothing and were not added; T. Rowe Price Investment Management was likewise confirmed at zero. The elevated total instead reflects genuine, unusually heavy concentration among Akamai's very largest holders: even the top 8 institutional rows alone (Vanguard through Bank of America) already sum to 62,080,245 shares, 43.2% of the company, before Point72, Fidelity, T. Rowe Price or any insider row is added. Capital Group's single-family stake of 7.88% is a particularly large concentrated active position, larger than BlackRock's index stake, and is flagged here as the most notable finding on the register side.
• Market cap is a computed figure: a live intraday Nasdaq quote ($113.03, 19 Aug 2026 3:50pm ET) multiplied by the 3 Aug 2026 10-Q cover-page share count (143,716,609). The two dates are about two weeks apart because no single source carries both a current price and a current share count; disclosed rather than treated as precise. AKAM's 52-week range per the same Nasdaq quote is $70.82 to $165.45, so the price has moved substantially since the 30 Jun 2026 register date (implied ~$118.2) and again since the 20 Feb 2026 proxy record date used for the insider rows.
• EDGAR's SC 13D/13G filing history for Akamai (CIK 0001086222) was checked in full: the most recent Schedule 13D (not an amendment) was filed in 2017, with the last 13D/A in 2018; nothing has been filed since. There is currently no active 13D-reporting strategic or activist holder, and no sovereign holder was found in any 13F or 13G/A reviewed.